Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphatic Metastasis × Ipilimumab × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Genitourinary 1

Conditions

Ovarian Neoplasms 14 Uterine Cervical Neoplasms 12 Carcinoma, Non-Small-Cell Lung 9 Melanoma 8 Endometrial Neoplasms 7 Triple Negative Breast Neoplasms 6 Stomach Neoplasms 6 Carcinoma, Transitional Cell 6 Squamous Cell Carcinoma of Head and Neck 5 Small Cell Lung Carcinoma 5 Carcinoma, Renal Cell 5 Fallopian Tube Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Merkel Cell 4 Carcinoma, Hepatocellular 4 Mesothelioma 3 Esophageal Neoplasms 3 Cholangiocarcinoma 3 Vulvar Neoplasms 2 Urinary Bladder Neoplasms 2 Seminoma 2 Sarcoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Myeloid, Acute 2 Histiocytoma, Malignant Fibrous 2

Interventions

sarcolipin 1 TP protocol 1 Positron Emission Tomography Computed Tomography 1 Nivolumab 1 Lymph Node Excision 1 Ipilimumab 1 Drug Therapy 1 Diffusion Magnetic Resonance Imaging 1 Cytoreduction Surgical Procedures 1 Cisplatin 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05504642 2023-04-18

CERAD-IMMUNE

Universitätsklinikum Köln

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡